File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: PARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy

TitlePARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy
Authors
Issue Date2013
PublisherAmerican Association for Cancer Research. The Journal's web site is located at http://mct.aacrjournals.org/
Citation
Molecular Cancer Therapeutics, 2013, v. 12 n. 11, p. 2517-2528 How to Cite?
AbstractNasopharyngeal carcinoma is a rare but highly invasive cancer. As options of agents for effectivecombination chemoradiotherapy for advanced nasopharyngeal carcinoma are limited, novel therapeutic approaches are desperately needed. The ubiquitin ligase CHFR is known to target PARP1 for degradation and is epigenetically inactivated in nasopharyngeal carcinoma. We present evidence that PARP1 protein is indeed overexpressed in nasopharyngeal carcinoma cells in comparison with immortalized normal nasopharyngeal epithelial cells. Tissue microarray analysis also indicated thatPARP1protein is significantly elevated in primary nasopharyngeal carcinoma tissues, with strong correlation with all stages of nasopharyngeal carcinoma development. We found that the PARP inhibitor AZD2281 (olaparib) increased DNA damage, cell-cycle arrest, and apoptosis in nasopharyngeal carcinoma cells challenged with ionizing radiation or temozolomide. Isobologram analysis confirmed that the cytotoxicity triggered by AZD2281 and DNAdamaging agents was synergistic. Finally, AZD2281 also enhanced the tumor-inhibitory effects of ionizing radiation in animal xenograft models. These observations implicate that PARP1 overexpression is an early event in nasopharyngeal carcinoma development and provide a molecular basis of using PARP inhibitors to potentiate treatment of nasopharyngeal carcinoma with radio- and chemotherapy. Mol Cancer Ther; 12(11); 2517-28. © 2013 AACR.
Persistent Identifierhttp://hdl.handle.net/10722/202509
ISSN
2015 Impact Factor: 5.579
2015 SCImago Journal Rankings: 3.224
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChow, JPH-
dc.contributor.authorMan, WY-
dc.contributor.authorMao, M-
dc.contributor.authorChen, H-
dc.contributor.authorCheung, FMF-
dc.contributor.authorNicholls, JM-
dc.contributor.authorTsao, GSW-
dc.contributor.authorLung, ML-
dc.contributor.authorPoon, RYC-
dc.date.accessioned2014-09-19T08:08:29Z-
dc.date.available2014-09-19T08:08:29Z-
dc.date.issued2013-
dc.identifier.citationMolecular Cancer Therapeutics, 2013, v. 12 n. 11, p. 2517-2528-
dc.identifier.issn1535-7163-
dc.identifier.urihttp://hdl.handle.net/10722/202509-
dc.description.abstractNasopharyngeal carcinoma is a rare but highly invasive cancer. As options of agents for effectivecombination chemoradiotherapy for advanced nasopharyngeal carcinoma are limited, novel therapeutic approaches are desperately needed. The ubiquitin ligase CHFR is known to target PARP1 for degradation and is epigenetically inactivated in nasopharyngeal carcinoma. We present evidence that PARP1 protein is indeed overexpressed in nasopharyngeal carcinoma cells in comparison with immortalized normal nasopharyngeal epithelial cells. Tissue microarray analysis also indicated thatPARP1protein is significantly elevated in primary nasopharyngeal carcinoma tissues, with strong correlation with all stages of nasopharyngeal carcinoma development. We found that the PARP inhibitor AZD2281 (olaparib) increased DNA damage, cell-cycle arrest, and apoptosis in nasopharyngeal carcinoma cells challenged with ionizing radiation or temozolomide. Isobologram analysis confirmed that the cytotoxicity triggered by AZD2281 and DNAdamaging agents was synergistic. Finally, AZD2281 also enhanced the tumor-inhibitory effects of ionizing radiation in animal xenograft models. These observations implicate that PARP1 overexpression is an early event in nasopharyngeal carcinoma development and provide a molecular basis of using PARP inhibitors to potentiate treatment of nasopharyngeal carcinoma with radio- and chemotherapy. Mol Cancer Ther; 12(11); 2517-28. © 2013 AACR.-
dc.languageeng-
dc.publisherAmerican Association for Cancer Research. The Journal's web site is located at http://mct.aacrjournals.org/-
dc.relation.ispartofMolecular Cancer Therapeutics-
dc.titlePARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy-
dc.typeArticle-
dc.identifier.emailCheung, FMF: cheungf@hku.hk-
dc.identifier.emailNicholls, JM: jmnichol@hkucc.hku.hk-
dc.identifier.emailTsao, GSW: gswtsao@hku.hk-
dc.identifier.emailLung, ML: mlilung@hku.hk-
dc.identifier.authorityNicholls, JM=rp00364-
dc.identifier.authorityTsao, GSW=rp00399-
dc.identifier.authorityLung, ML=rp00300-
dc.identifier.doi10.1158/1535-7163.MCT-13-0010-
dc.identifier.pmid23979918-
dc.identifier.scopuseid_2-s2.0-84887488909-
dc.identifier.hkuros240215-
dc.identifier.volume12-
dc.identifier.issue11-
dc.identifier.spage2517-
dc.identifier.epage2528-
dc.identifier.isiWOS:000326886000021-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats